Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT07737951 · Thomas Jefferson University

Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

What this study is about

The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA in women with hormone receptor positive stage I-III BCa. The investigators will pilot test our data collection for mechanism measures via three innovatively integrated biobehavioral pathways.

View original scientific description

The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA in women with hormone receptor positive stage I-III BCa. The investigators will pilot test our data collection for mechanism measures via three innovatively integrated biobehavioral pathways.

Interventions

BEHAVIORAL

Tai Chi

Routine virtual Tai Chi group classes via Zoom for 1 hour, twice a week, for 12 weeks, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow-up.

BEHAVIORAL

Health Education

Routine virtual AC classes delivered remotely, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow up.

Primary outcome measures

Consent Rate

Time frame: Up to 6 months

Percentage of eligible participants who consent and enroll in the study.

Engagement Rate

Time frame: 12 weeks

Percentage of intervention sessions attended by enrolled participants.

Retention Rate

Time frame: 20 weeks

Percentage of participants completing study follow up assessments.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • -Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study:
  • Age ≥18 years
  • Diagnosis of stage I-III hormone receptor-positive breast cancer
  • Postmenopausal
  • Currently receiving an aromatase inhibitor (anastrozole, letrozole, or exemestane) or within 5 years of initiation
  • Report joint pain that started or worsened after initiation of AI therapy
  • Report worst pain in the past week ≥3 on the BPI (0-10 scale)
  • Able to complete study procedures in English
  • Willing to be randomized to an intervention or attention control group and adhere to study procedures

Exclusion criteria

  • -An individual who meets any of the following criteria will be excluded from participation in this study:
  • Undergoing active cancer treatment (excluding endocrine therapy)
  • Uncontrolled cardiac or pulmonary disease that would limit safe participation
  • Currently engaged in regular structured moderate- or vigorous-intensity exercise (e.g., brisk walking, jogging/running, cycling, swimming, aerobic classes, or resistance training) totaling ≥150 minutes per week over the past 3 months
  • Currently participating in Tai Chi, yoga, Pilates, or other structured mind-body practice ≥2 times per week over the past 3 months
  • Joint pain due to inflammatory arthritic conditions
  • Recent surgery or joint injection within the past 4-6 weeks
  • Initiation or dose change of corticosteroids or opioids within the past 4 weeks
  • Planned discontinuation of AI therapy within the next 6 months
  • This study is limited to women with breast cancer, as \<1% of cases occur in men and data on AIIA in male patients are limited

Where

  • Philadelphia, Pennsylvania

Related conditions & keywords

Hormone Receptor Positive Breast CarcinomaPostmenopausalBreast CancerAnatrozoleLetrozoleExemestaneTai Chi

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Aug 14, 2026 · Source of record for eligibility and locations

📊
1 of 40 participants interested
3% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Philadelphia

Pennsylvania

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Breast Cancer Trials by City

Browse all breast cancer clinical trials in these cities — not just this study.

Looking for Hormone Receptor Positive Breast Carcinoma Treatment in Philadelphia?

Join others in Pennsylvania exploring innovative treatment options through clinical research

Hormone Receptor Positive Breast Carcinoma Treatment Options in Philadelphia, Pennsylvania

If you're searching for Hormone Receptor Positive Breast Carcinoma treatment in Philadelphia, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Philadelphia and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Hormone Receptor Positive Breast Carcinoma. All study-related care is provided at no cost to participants.

Local Sites
1 locations in Pennsylvania
Now Enrolling
Up to 40 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Hormone Receptor Positive Breast Carcinoma?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Hormone Receptor Positive Breast Carcinoma

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Hormone Receptor Positive Breast Carcinoma Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT07737951. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.